Effects of DHA on STVQT in vivo. (A) Representative examples of short term variability of QT measured in WT and LQT2 rabbits before (left) and after (right) administration of DHA. (B) Histograms showing STVQT before (fully coloured columns) and after (dotted columns) administration of DHA in WT, LQT1, LQT2, LQT2–5, and LQT5 rabbits. Differences are indicated with * for P-value < 0.050. All data are presented as mean ± SEM. (C) Histograms showing a comparison between STVQT in transgenic LQTS rabbits treated with DHA vs. baseline STVQT in WT animals (grey); a normalization in LQT2 can be observed (lack of significant differences between LQT2+DHA and WT at baseline). Differences are indicated as * for P-value <0.050, and as ** for P-value <0.010. All data are presented as mean ± SEM. Grey bars are repeated to better show the difference to WT for each individual genotype. DHA, docosahexaenoic acid; LQTS, long QT syndrome; LQT1, long QT Type 1; LQT2, long QT Type 2; LQT5, long QT Type 5; LQT2–5, combined form of long QT Types 2 and 5; STVQT, short-term variability of QT interval; SEM, standard error of the mean; WT, wild type.